Attached files
| file | filename |
|---|---|
| 10-K - Emergent BioSolutions Inc. | form10-k.htm |
| EX-31.1 - Emergent BioSolutions Inc. | exhibit31-1.htm |
| EX-23.1 - Emergent BioSolutions Inc. | exhibit23.htm |
| EX-21 - Emergent BioSolutions Inc. | exhibit21.htm |
| EX-12.1 - Emergent BioSolutions Inc. | exhibit12.htm |
| EX-10.6 - Emergent BioSolutions Inc. | exhibit10-6.htm |
| EX-10.5 - Emergent BioSolutions Inc. | exhibit10-5.htm |
| EX-10.24 - Emergent BioSolutions Inc. | exhibit10-24.htm |
| EX-32.2 - Emergent BioSolutions Inc. | exhibit32-2.htm |
| EX-31.2 - Emergent BioSolutions Inc. | exhibit31-2.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Emergent BioSolutions Inc. (the "Company") for the period ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Daniel Abdun-Nabi, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 27, 2017
/s/DANIEL J. ABDUN-NABI
Daniel J. Abdun-Nabi
Chief Executive Officer